Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Hand, Foot, and Mouth Disease Outbreak What You Need to Know

Author(s): Amandeep Singh*, Okesanya Olalekan John and Bello Barakat Bisola

Volume 23, Issue 7, 2023

Published on: 01 August, 2023

Article ID: e010623217547 Pages: 5

DOI: 10.2174/1871526523666230601121101

Price: $65

Abstract

HFMD is an obvious disease in children mostly below the age of five constituting a public health challenge to Asian-Pacific and developing countries majorly. This disease is often caused by enterovirus 71 (EV71) and Coxsackievirus A16. HFMD is a mild degree fever and general illness which manifests for about 10 days. Young age, male gender, poor hygiene, and high social contacts are some risk factors. HFMD can be diagnosed clinically by isolating the virus from stool and pharynx and identifying it on Light microscopic examination. Polymerase Chain Reaction Assay is a gold standard for confirming the virus from swabbed lesions. Late confirmation could lead to severe complications. There are no specific treatments and vaccines licensed for general use in the treatment of various serotypes of HFMD. The major strategy to prevent and control this disease is to strictly follow the WHO 8 guidelines to curb the spread of the disease.

[1]
Kimmis BD, Downing C, Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis 2018; 102(5): 353-6.
[PMID: 30566537]
[2]
Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10(11): 778-90.
[http://dx.doi.org/10.1016/S1473-3099(10)70194-8] [PMID: 20961813]
[3]
Aswathyraj S, Arunkumar G, Alidjinou EK, Hober D. Hand, Foot And Mouth Disease (HFMD): Emerging epidemiology and the need for a vaccine strategy. Med Microbiol Immunol 2016; 205(5): 397-407.
[http://dx.doi.org/10.1007/s00430-016-0465-y] [PMID: 27406374]
[4]
Guerra AM, Orille E, Waseem M. Hand Foot And Mouth Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431082/
[5]
Liu Z, Tian J, Wang Y, et al. The burden of hand, foot, and mouth disease among children under different vaccination scenarios in China: A dynamic modelling study. BMC Infect Dis 2021; 21(1): 650.
[http://dx.doi.org/10.1186/s12879-021-06157-w] [PMID: 34225650]
[6]
Wu H, Xue M, Wu C, et al. Trend of hand, foot, and mouth disease from 2010 to 2021 and estimation of the reduction in enterovirus 71 infection after vaccine use in Zhejiang Province, China. Chong KC, editor. PLoS One. 2022; 17: p. (9)e0274421.
[7]
Seddon JH, Duff MF. Hand-foot-and-mouth disease: Coxsackie virus types A 5, A 10, and A 16 infections. N Z Med J 1971; 74(475): 368-73.
[PMID: 5291880]
[8]
Shimizu H, Nakashima K. Surveillance of hand, foot, and mouth disease for a vaccine. Lancet Infect Dis 2014; 14(4): 262-3.
[http://dx.doi.org/10.1016/S1473-3099(13)70330-X] [PMID: 24485992]
[9]
Ooi EE, Phoon MC, Ishak B, Chan SH. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis 2002; 8(9): 995-7.
[http://dx.doi.org/10.3201/eid0809.010397] [PMID: 12194783]
[10]
Kua JA, Pang J. The epidemiological risk factors of hand, foot, mouth disease among children in Singapore: A retrospective case-control study. PLoS One 2020; 15(8)e0236711
[http://dx.doi.org/10.1371/journal.pone.0236711]
[11]
Park SK, Park B, Ki M, et al. Transmission of seasonal outbreak of childhood enteroviral aseptic meningitis and hand-foot-mouth disease. J Korean Med Sci 2010; 25(5): 677-83.
[http://dx.doi.org/10.3346/jkms.2010.25.5.677] [PMID: 20436701]
[12]
Saguil A, Kane SF, Lauters R, Mercado MG. Hand-foot-and-mouth disease: Rapid evidence review. Am Fam Physician 2019; 100(7): 408-14.
[PMID: 31573162]
[13]
Li XW, Ni X, Qian SY, et al. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition). World J Pediatr 2018; 14(5): 437-47.
[http://dx.doi.org/10.1007/s12519-018-0189-8] [PMID: 30280313]
[14]
Chen KR, Ling P. Interplays between Enterovirus A71 and the innate immune system. J Biomed Sci 2019; 26(1): 95.
[http://dx.doi.org/10.1186/s12929-019-0596-8] [PMID: 31787104]
[15]
Zhang X, Zhang Y, Li H, Liu L. Hand-foot-and-mouth disease-associated enterovirus and the development of multivalent HFMD vaccines. Int J Mol Sci 2022; 24(1): 169.
[http://dx.doi.org/10.3390/ijms24010169] [PMID: 36613612]
[16]
Lim HX, Poh CL. Insights into innate and adaptive immune responses in vaccine development against EV-A71. Ther Adv Vaccines Immunother 2019; 7.
[http://dx.doi.org/10.1177/2515135519888998] [PMID: 31799495]
[17]
Wu Y, Shang S, Chen Z, Yang Z. Analysis of the epidemic characteristics of the etiological agents in children with hand, foot and mouth disease and its clinical significance Chinese J Pediatr 2010; 48(7): 535-9.
[18]
Broccolo F, Drago F, Ciccarese G, et al. Possible long-term sequelae in hand, foot, and mouth disease caused by Coxsackievirus A6. J Am Acad Dermatol 2019; 80(3): 804-6.
[http://dx.doi.org/10.1016/j.jaad.2018.08.034] [PMID: 30661911]
[19]
Gonzalez G, Carr MJ, Kobayashi M, Hanaoka N, Fujimoto T. Enterovirus-associated hand-foot and mouth disease and neurological complications in japan and the rest of the world. Int J Mol Sci 2019; 20(20): 5201.
[http://dx.doi.org/10.3390/ijms20205201] [PMID: 31635198]
[20]
Ni XF, Li X, Xu C, et al. Risk factors for death from hand-foot-mouth disease: A meta-analysis. Epidemiol Infect 2020; 148e44
[http://dx.doi.org/10.1017/S0950268819002279] [PMID: 32102711]
[21]
Coates SJ, Davis MDP, Andersen LK. Temperature and humidity affect the incidence of hand, foot, and mouth disease: A systematic review of the literature - a report from the International Society of Dermatology Climate Change Committee. Int J Dermatol 2019; 58(4): 388-99.
[http://dx.doi.org/10.1111/ijd.14188] [PMID: 30187452]
[22]
Huang X, Zhang X, Wang F, Wei H, Ma H, Sui M. Clinical efficacy of therapy with recombinant human interferon α1b in hand, foot, and mouth disease with enterovirus 71 infection. Horwitz MS, editor. PLoS One 2016; 11(2): e0148907.
[23]
Velástegui J, Cova L, Galarza Y, Fierro P, León Baryolo L, Bustillos A. A case report of hand, foot, and mouth disease with necrotizing mucocutaneous lesions. Medwave 2019; 19(7): e7683-3.
[http://dx.doi.org/10.5867/medwave.2019.07.7683] [PMID: 31442216]
[24]
Chea S, Cheng Y, Chokephaibulkit K, et al. Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia. Emerg Infect Dis 2015; 21(1)e140992
[http://dx.doi.org/10.3201/eid2101.140992] [PMID: 25531166]
[25]
Nayak G, Bhuyan SK, Bhuyan R, Sahu A, Kar D, Kuanar A. Global emergence of Enterovirus 71: A systematic review. Beni Suef Univ J Basic Appl Sci 2022; 11(1): 78.
[http://dx.doi.org/10.1186/s43088-022-00258-4] [PMID: 35730010]
[26]
Ye N, Gong X, Pang L, et al. Cytokine responses and correlations thereof with clinical profiles in children with enterovirus 71 infections. BMC Infect Dis 2015; 15(1): 225.
[http://dx.doi.org/10.1186/s12879-015-0965-1] [PMID: 26058678]
[27]
World Health Organisation. A guide to clinical management and public health response for hand, foot and mouth disease. HFMD 2011.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy